Senti Bio to present logic-gated CAR-NK cell therapy at BioScience Forum

SOUTH SAN FRANCISCO - Senti Biosciences, Inc. (NASDAQ:SNTI), a biotechnology company currently trading near $1.95 and showing significant volatility according to InvestingPro data, announced it will present at the BioScience Forum in San Carlos, California on Wednesday, July 23.

The presentation, titled "Using Logic Gated CARs to Drive Cancer Treatment," will be delivered by Kanya Rajangam, President, Head of Research & Development and Chief Medical Officer of Senti Bio at 6:00 PM PT.

According to the press release, the presentation will highlight the company’s novel first-in-class logic-gated CAR-NK cell therapy, which is designed to kill leukemic cells while protecting healthy bone marrow.

Senti Bio develops cell and gene therapies using its proprietary Gene Circuit platform. The company’s technology aims to engineer Gene Circuits that can precisely target cancer cells while sparing healthy cells. InvestingPro analysis indicates the company maintains strong liquidity with a current ratio of 4.22, though it faces significant cash burn challenges typical of early-stage biotech firms.

The BioScience Forum is a non-profit educational organization serving the Bay Area biotechnology community, featuring presentations from researchers and executives on developments in the life sciences industry.

Senti Bio’s wholly-owned pipeline consists of cell therapies engineered with Gene Circuits targeting various liquid and solid tumor indications. The company reports that its Gene Circuits have shown preclinical efficacy in both NK and T cells.

The biotechnology firm is also exploring applications of its Gene Circuit technology beyond oncology through partnerships, based on preclinical demonstrations in other modalities and diseases.

In other recent news, Senti Biosciences reported promising preliminary results from its Phase 1 clinical trial of SENTI-202, a potential treatment for relapsed or refractory hematologic malignancies, including acute myeloid leukemia (AML). The study showed no dose-limiting toxicities, and five out of seven evaluable patients achieved an overall response rate, with several achieving complete remission. The U.S. Food and Drug Administration granted Orphan Drug Designation to SENTI-202, which offers potential benefits such as tax credits and market exclusivity. Senti Biosciences also shared preliminary financial results for the first quarter of 2025, reporting a net loss of $14.1 million and cash reserves of approximately $33.8 million.

In a strategic move, Senti Bio appointed Bryan Baum, Co-Founder of K5 Global, to its Board of Directors. Baum brings extensive entrepreneurial experience, having founded and sold multiple ventures. Laidlaw analysts initiated coverage on Senti Biosciences with a Buy rating, highlighting the company’s focus on developing SENTI-202 for AML treatment. The analysts expressed optimism about the therapy’s novel approach to cancer treatment. Additionally, Senti Bio released an animated video illustrating SENTI-202’s mechanism of action, further engaging the scientific community and stakeholders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.